S

    Sellas Life Sciences Group Inc (SLS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $13.21
    -2.00 (-13.15%)

    Market Cap: $2.67B

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    57%(23/40)
    Avg Surprise
    -170.74%

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.06
    Range$-0.06 - $-0.05
    2 analysts
    EPS Revisions
    1
    0
    7d
    1
    1
    30d
    EPS Estimate Drift
    90d ago$-0.07-33.3%
    60d ago$-0.07-27.3%
    30d ago$-0.06+0.0%
    7d ago$-0.06+0.0%
    Current$-0.06
    Revenue Consensus
    $0
    Range$0 - $0
    1 analysts
    Dec 31, 2026
    EPS Consensus$-0.04
    Range$-0.04 - $-0.04
    1 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    1 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.04---
    Sep 26EST
    		-$-0.06---
    Jun 26
    		$-0.05$-0.04-25.00%Miss+28.6%
    Mar 26
    		$-0.05$-0.07+30.43%Beat+30.4%
    Dec 25
    		$-0.05$-0.06+16.67%Beat+37.5%
    Sep 25
    		$-0.06$-0.08+25.00%Beat+40.0%
    Jun 25
    		$-0.07$-0.08+12.50%Beat+46.2%
    Mar 25
    		$-0.07$-0.11+36.36%Beat+66.7%
    Dec 24
    		$-0.08$-0.11+25.02%Beat+68.0%
    Sep 24
    		$-0.10$-0.13+23.08%Beat+69.7%
    Jun 24
    		$-0.13$-0.17+23.53%Beat+58.1%
    Mar 24
    		$-0.21$-0.16-31.25%Miss+55.3%
    Dec 23
    		$-0.25$0.09-377.78%Miss+41.9%
    Sep 23
    		$-0.33$0.02-1750.00%Miss+2.9%
    Jun 23
    		$-0.31$-0.35+11.43%Beat+26.2%
    Mar 23
    		$-0.47$-0.29-62.07%Miss-11.9%
    Dec 22
    		$-0.43$-0.32-34.38%Miss-2.4%
    Sep 22
    		$-0.34$-0.39+12.82%Beat+24.4%
    Jun 22
    		$-0.42$-0.37-13.51%Miss-40.0%
    Mar 22
    		$-0.42$-0.42+0.00%Beat-162.5%
    Dec 21
    		$-0.42$-0.41-2.44%Miss-50.0%
    Sep 21
    		$-0.45$-0.34-32.35%Miss+15.1%
    Jun 21
    		$-0.30$-0.39+23.08%Beat+52.4%
    Mar 21
    		$-0.16N/A+55.56%Beat+74.6%
    Dec 20
    		$-0.28$-0.28+0.00%Beat+81.8%
    Sep 20
    		$-0.53$-0.34-55.88%Miss+44.8%
    Jun 20
    		$-0.63$-0.64+1.56%Beat+89.8%
    Mar 20
    		$-0.63$-0.68+7.35%Beat+93.5%
    Dec 19
    		$-1.54$-0.72-113.89%Miss+81.9%
    Sep 19
    		$-0.96$-1.00+4.00%Beat+96.4%
    Jun 19
    		$-6.19$-9.00+31.22%Beat+90.2%
    Mar 19
    		$-9.71$-10.25+5.27%Beat+88.4%
    Dec 18
    		$-8.50$-11.75+27.66%Beat+82.8%
    Sep 18
    		$-26.50$-20.25-30.86%Miss+11.7%
    Jun 18
    		$-63.00$-51.50-22.33%Miss+80.9%
    Mar 18
    		$-83.50$-46.50-79.57%Miss+87.6%
    Dec 17
    		$-49.50$-1.06-4569.81%Miss+93.3%
    Sep 17
    		$-30.00N/A+86.67%Beat+96.7%
    Jun 17
    		$-330.00$-270.00-22.22%Miss-
    Mar 17
    		$-675.00$-330.00-104.55%Miss-
    Dec 16
    		$-735.00$-780.00+5.77%Beat-
    Sep 16
    		$-900.00$-1350.00+33.33%Beat-

    Key Metrics

    Valuation
    P/E Ratio-63.30EV/EBITDA-1.71x
    Price/FCF-87.93xFCF Yield-1.14%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-39.60%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio18.83xQuick Ratio18.83x
    Trading Statistics
    Beta2.49Avg Volume6.82M
    52-Week High$15.8852-Week Low$1.39

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$13.94
    SMA 20$12.85
    SMA 50$12.34
    SMA 200$6.50
    EMA 10$13.74
    EMA 20$13.15
    EMA 50$11.87
    EMA 200$7.60

    MACD

    Line: 0.73Signal: 0.63Hist: 0.10

    ADX

    ADX: 34.7+DI: 28.0-DI: 12.4

    Aroon & PSAR

    Aroon Up80.0
    Aroon Down8.0
    PSAR$15.58

    Bollinger Bands

    Upper Band$15.49
    Lower Band$10.21
    %B Position4107%(Upper)
    Band Width0.57

    RSI (14-Day)

    Neutral
    51.9

    Momentum Oscillators

    Stoch %K66.4
    Stoch %D68.4
    Williams %R-51.0
    ROC (10d)3.4%
    Momentum0.43
    CCI (20d)53.5
    MFI (14d)59.4

    Volatility Measures

    ATR (14d)$1.31(9.9%)
    StdDev (20d)1.32
    Hist Vol109.9%(High)

    Volume Flow

    VWAP$13.72
    OBV264.7M
    AD Line98.0M
    CMF (20d)0.080

    Volume Metrics

    Avg Vol (20d)7.0M
    Vol Ratio1.4x
    VWMA (20d)$13.23

    Pivot Points

    R3$17.52
    R2$16.54
    R1$15.87
    Pivot Point$14.90
    S1$14.23
    S2$13.25
    S3$12.59

    Advanced Oscillators

    TSI16.51
    Ultimate Osc47.2
    KST145.75

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$0$0$0$0$0$0
    Cost of Revenue$0$0N/A$0$0$0N/A$0$0$0$0$0
    Gross Profit$0$0N/A$0$0$0N/A$0$0$0$0$0
    Operating Expenses$10.63M$9.25M$8.26M$7.08M$6.87M$6.06M$6.92M$7.33M$7.62M$9.64M$8.18M$9.36M
    R&D$6.27M$5.13M$4.73M$4.22M$3.87M$3.21M$4.44M$4.36M$5.19M$5.11M$5.10M$5.81M
    SG&A$4.36M$4.12M$3.52M$2.87M$3.00M$2.86M$2.48M$2.97M$2.44M$4.53M$3.08M$3.55M
    Operating Income$-10,629,000$-9,252,000$-8,255,000$-7,083,000$-6,873,000$-6,063,000$-6,918,000$-7,329,000$-7,621,000$-9,645,000$-8,177,000$-9,361,000
    Interest Income$1.02M$845,000$597,000$292,000$272,000$250,000$181,000$221,000$151,000$79,000$0$94,000
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-9,605,000$-8,407,000$-7,658,000$-6,791,000$-6,601,000$-5,813,000$-6,737,000$-7,108,000$-7,470,000$-9,566,000$-8,136,000$-9,267,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-9,605,000$-8,407,000$-7,658,000$-6,791,000$-6,601,000$-5,813,000$-6,737,000$-7,108,000$-7,470,000$-9,566,000$-8,136,000$-9,267,000
    EBITDA$-10,475,000$-9,099,000$-8,101,000$-7,083,000$-6,724,000$-5,916,000$-6,770,000$-7,329,000$-7,621,000$-9,507,000$-8,177,000$-9,239,000
    EBIT$-10,629,000$-9,252,000$-8,255,000$-7,083,000$-6,873,000$-6,063,000$-6,918,000$-7,329,000$-7,621,000$-9,645,000$-8,177,000$-9,361,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about SLS

    News

    SLS Stock Charges Ahead As AML Trial Buzz Builds: Report Claims Regal Hit 80th Event — Retail Isn’t Convinced

    Shares of Sellas Life Sciences (SLS) surged after a German report claimed its Regal leukemia trial reached its 80th event, a key threshold for final efficacy analysis. While the company has not officially confirmed this, the news has generated significant discussion among retail investors. Sellas also anticipates initial data from its SLS009 trial in Q4, and positive cancer vaccine data from Moderna has further boosted optimism for its pipeline.

    Yahoo Finance•8/24/26•
    Bullish

    SELLAS Life Sciences Group stock Analysis: 5-Day Bullish Surge & Valuation Test

    SELLAS Life Sciences Group (SLS) stock has surged over 20% in five days, closing at 15.46, driven by strong momentum and an unambiguously bullish trend across multiple timeframes. Despite this impressive rally, the stock is approaching overbought conditions with its RSI near 70 and price trading above the upper Bollinger Band, suggesting a potential for a pause or pullback. The bullish case is supported by consistent EMA alignment and oncology sector tailwinds, while concerns include unconfirmed trial catalysts, retail skepticism, and the company's reported net losses, making it a high-momentum, high-risk setup.

    The Cryptonomist•8/24/26•
    Somewhat-Bullish

    SLS Stock Charges Ahead As AML Trial Buzz Builds: Report Claims Regal Hit 80th Event — Retail Isn’t Convinced

    Shares of Sellas Life Sciences (SLS) surged after a German report claimed its Regal leukemia trial reached its 80th event, a key milestone for final efficacy analysis. However, Sellas has not officially confirmed this, leading to skepticism among retail investors despite the positive buzz. The company expects initial data for its SLS009 candidate in Q4 and ended Q2 with $138.3 million in cash.

    Stocktwits•8/23/26•
    Somewhat-Bullish

    Sellas Life Sciences: Options Traders Pile In as a Leukemia Trial Reaches Its Defining Threshold

    Options traders are heavily investing in Sellas Life Sciences as its pivotal Phase 3 REGAL trial for acute myeloid leukemia reached the 80 pre-specified death events required for final efficacy analysis, with overall survival data expected in Q4. The stock surge was also influenced by positive sector news from Moderna and Merck, validating cancer vaccines. Despite widening net losses, the company maintains a strong cash position and has another promising drug, SLS009, in its pipeline, attracting institutional interest.

    aktiencheck.de•8/23/26•
    Neutral

    Are SELLAS Life Sciences (SLS) Loss Trends Masking a Shifting Cancer Vaccine Investment Narrative?

    SELLAS Life Sciences Group (SLS) reported increased net losses in Q2 2026, yet basic loss per share improved. This comes amidst renewed investor interest in immune-based cancer therapies, influenced by positive Phase 3 cancer vaccine updates from larger pharmaceutical companies. The article suggests that despite wider cash burn, the shifting sentiment towards cancer vaccines and the potential of SELLAS's immunotherapy platform could be influencing its investment narrative, though the company still faces funding risks and relies on key clinical trial readouts.

    Simply Wall Street•8/22/26•
    Neutral

    Frequently Asked Questions About SLS

    Does SLS pay dividends?
    Sellas Life Sciences Group Inc (SLS) does not currently pay a regular dividend.
    What is SLS's market cap?
    Sellas Life Sciences Group Inc (SLS) has a market capitalization of $2.67B with a current stock price of $13.21.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In